

S230: The research of Prospekt III (prostamol: perspectives of combined therapy) of BHP

Gurzhenko I.

Institution Of Urology, Dept. of Andrology, Kiev, Ukraine

INTRODUCTION & OBJECTIVES: The estimation of efficiency of the complex therapy by the medicines FLOSIN and PROSTAMOL UNO in 128 patients with Benign Prostatic Hyperplasia (BHP) of the second stage was carried out. AIM of WORK: to estimate the efficiency and bearableness of the protracted combined therapy by medicines FLOSIN and PROSTAMOL UNO in patients with BHP of II stage, by comparison to combination of finasteride+doxasosin. All patients, as well as before, were divided in two groups. The first group (clinical) included 128 patients with BHP of the II stage. The second group(control) consisted of 30 patients with BHP of II stage.

MATERIAL & METHODS: The patients of a 1st group took medicines FLOSIN MP (1 pill once a day in a dosage 0,4 mgs, in the morning after-meal) and PROSTAMOL UNO (1 capsule per day in the evening). Patients from the 2nd group took medicines of Doxasosin (1 pill once a day before the sleep in a dosage 2 mgs) and Finasteride (1 pill of 5 mgs once a day) during three years.

RESULTS: The improvement of different degree of expressed was marked by 93,7% of patients of a 1st group and 90% of patients 2nd group in 3 months of therapy. By the end of 3rd year of the treatment the percent of improvement increased in a 1st group to 96,9%, and in 2nd - 93,3%. The efficiency of the treatment has made 96,9% with low frequency of adverse events. At 3 from a 128 patients (2,3%) of a 1st group by-effects were marked as dizziness, and retrograde ejaculation was marked at 4 (3,1%) patients. And for patients 2nd group by-effects as dizziness and headache were marked at 6(20,0%) from 30 patients. For 4(13,3%) patients the decline of erection and violation of orgasm was marked, and a libido went down at 12(40,0%). Thus, all the by-effects were marked at 13 (43,3%) from 30 patients. Difference on the index of by-effects at patients from 1st (5,4%) and of 2nd (43,3%) group reliable.

CONCLUSIONS: The received results allow recommending Flosin and Prostamol Uno for using in andrological practice.

Eur Urol Suppl 2014; 13(7) e1555